Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Apomorphine · Apokyn, Kynmobi

Small molecule · developed by Mdd Us

Approved FDA, Apr 2004
1 Registered trials

What is Apomorphine?

Apomorphine is given by continuous subcutaneous infusion through a portable external electronic pump.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Apokyn, Kynmobi, Onapgo
Drug type
Small molecule
Therapy area
Neurology
Developer
Mdd Us
In trials of
SUPN
FDA status
Approved as Apokyn, Kynmobi, Onapgo (April 20, 2004), NDA021264

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02339064 Phase 3 Idiopathic Parkinson's Disease Active not recruiting SUPN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Parkinson's Disease

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.